key: cord-0923387-2isz8wwn
authors: Kalra, Suprita
title: Prevention and Control of COVID-19 in Chronic Kidney Disease: Correspondence
date: 2020-07-07
journal: Indian J Pediatr
DOI: 10.1007/s12098-020-03398-6
sha: f81ca7849b45d1e285664219ca02de6afae7d097
doc_id: 923387
cord_uid: 2isz8wwn

nan

1. Many papers published on this aspect have stated that it may be too simplistic to believe that increased expression and activity of ACE-2 by ARBs may worsen SARS-Coronavirus lung injury or Acute kidney injury and some contradicting evidence has been cited which says that they may actually be beneficial [3, 4] .

Society of Hypertension (ESH) and the European Society of Cardiology has clarified that treatment with ACEIs or ARBs should continue in patients with CKD in the same manner except in presence of severe symptoms or hemodynamic instability where their use may be discontinued [5, 6] .

We therefore request the authors to reconsider their suggestion on discontinuation of ACEIs and ARBs in all children with CKD with COVID-19 disease.

To the Editor: I have read the proposal of Dr. Suprita Kalra carefully. In our article entitled 'Prevention and control of COVID-19 in chronic kidney disease' published in Indian Journal of Pediatrics, we proposed that the pathogenesis of 2019-nCoV is similar to that of SARS virus [1] [2] [3] [4] , which infects human cells by recognizing and binding to angiotensin converting enzyme (ACE)-2 protein; the use of ACE inhibitors (ACEIs) and angiotensin receptor antagonists (ARBs) can increase the expression and activity of ACE-2 [5] . Therefore, it is suggested that ACEI and ARB should be discontinued in children with COVID-19 and other antihypertensive drugs should be used instead.

Dr. Suprita Kalra has different opinion on the above points, but we think that the points raised by both of us are based on animal experiments, while novel coronavirus is a new virus. We both have just put forward one point of view, which needs to be further confirmed and more studies are needed.

Prevention and control of COVID-19 in chronic kidney disease

ACE2 expression is induced by treatment with ACE-inhibitors (ACEIs) or angiotensin II AT1 receptor blockers (ARBs) in many rodent tissues

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway

ESH Statement on COVID-19. Available at

Available at: https:// www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/ position-statement-of-the-esccouncil-on-hypertension-on-aceinhibitorsand-ang

Prevention and control of COVID-19 in chronic kidney disease

Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV

ACE2 expression is induced by treatment with ACE-inhibitors (ACEIs) or angiotensin II AT1 receptor blockers (ARBs) in many rodent tissues